U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H32O8.C21H26ClN3OS
Molecular Weight 864.485
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PREDNAZATE

SMILES

OCCN1CCN(CCCN2C3=CC=CC=C3SC4=CC=C(Cl)C=C24)CC1.C[C@]56C[C@H](O)[C@H]7[C@@H](CCC8=CC(=O)C=C[C@]78C)[C@@H]5CC[C@]6(O)C(=O)COC(=O)CCC(O)=O

InChI

InChIKey=QKKLKGVIECOSRM-CODXZCKSSA-N
InChI=1S/C25H32O8.C21H26ClN3OS/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30;22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h7,9,11,16-18,22,27,32H,3-6,8,10,12-13H2,1-2H3,(H,29,30);1-2,4-7,16,26H,3,8-15H2/t16-,17-,18-,22+,23-,24-,25-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C21H26ClN3OS
Molecular Weight 403.969
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C25H32O8
Molecular Weight 460.5168
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Prednisolone is a synthetic adrenocortical steroid drug with predominantly glucocorticoid properties. Some of these properties reproduce the physiological actions of endogenous glucocorticosteroids, but others do not necessarily reflect any of the adrenal hormones’ normal functions; they are seen only after administration of large therapeutic doses of the drug. The pharmacological effects of prednisolone which are due to its glucocorticoid properties include: promotion of gluconeogenesis; increased deposition of glycogen in the liver; inhibition of the utilization of glucose; anti-insulin activity; increased catabolism of protein; increased lipolysis; stimulation of fat synthesis and storage; increased glomerular filtration rate and resulting increase in urinary excretion of urate (creatinine excretion remains unchanged); and increased calcium excretion. Prednisolone is used to treat certain types of allergies, inflammatory conditions, autoimmune disorders, and cancers. Some of these conditions include adrenocortical insufficiency, high blood calcium, rheumatoid arthritis, dermatitis, eye inflammation, asthma, and multiple sclerosis.

CNS Activity

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Sixtysix-20
Primary
Prednisolone
Primary
Prednisolut
Primary
OMNIPRED
Primary
OMNIPRED
Primary
OMNIPRED
Primary
Prednisolone
Primary
Prednisolut
Primary
Prednisolone
Primary
Prednisolone
Primary
Prednisolut
Primary
OMNIPRED
Primary
Prednisolone
Primary
Prednisolone
Primary
Prednisolone
Primary
Prednisolut
Primary
OMNIPRED
Primary
Prednisolut
Primary
Prednisolone
Primary
Prednisolone
PubMed

PubMed

TitleDatePubMed
Intravenous hydrocortisone hemisuccinate and prednisolone hemisuccinate.
1956 Dec
[Pharmacokinetics and pharmacodynamics of prednisolone following extremely high dosage as prednisolone hemisuccinate].
1987 Feb
In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis.
1987 Sep
Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone.
1988 Nov
Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone.
1993
Prednisone is more effective than prednisolone metasulfobenzoate in the treatment of bullous pemphigoid.
1999 Jan
Inhibition of calcineurin activity and protection against cyclosporine A induced cytotoxicity by prednisolone sodium succinate in human peripheral mononuclear cells.
2000 Jun
Comparison of suppressive potency between prednisolone and prednisolone sodium succinate against mitogen-induced blastogenesis of human peripheral blood mononuclear cells in-vitro.
2001 May
Effects of octreotide acetate and amniotic membrane on wound healing in experimental glaucoma surgery.
2003 Sep
[Acceptability and tolerance of prednisolone metasulfobenzoate in orally dispersing tablets in 2 to 12-years-old children].
2004 Sep
Prednisolone oral solution plus inhaled procaterol for acute asthma in children: a double-blind randomized controlled trial.
2007 Sep-Oct
Effects of prednisolone on the systemic release of mediators of cell-mediated cytotoxicity during human endotoxemia.
2008 Apr
Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis.
2008 Feb 1
"ChilDrive": a technique of combining regional cutaneous hypothermia with iontophoresis for the delivery of drugs to synovial fluid.
2009 Nov
11,20-Dihy-droxy-3-oxopregna-1,4-dien-21-oic acid monohydrate.
2011 Jun 1
Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).
2012 Feb
Protective effect of selected calcium channel blockers and prednisolone, a phospholipase-A2 inhibitor, against gentamicin and carbon tetrachloride-induced nephrotoxicity.
2014 Aug
The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial.
2014 Feb
Preparation, characterization and evaluation of novel elastic nano-sized niosomes (ethoniosomes) for ocular delivery of prednisolone.
2014 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Two drops topically in the eye(s) four times daily.
Route of Administration: Topical ophthalmic
In Vitro Use Guide
Human polymorphonuclear leukocytes (PMNLs) were incubated for 60 min with 20 microM or 100 microM prednisolone, and stimulated thereafter for 1 min with 10 nM leukotriene B4 (LTB4), 10 nM leukotriene C4 (LTC4), 10 nM leukotriene D4 (LTD4) or 10 microM histamine. PMNLs spontaneously released thromboxane B2 (TXB2) during 60 min incubation, and the rate of formation was significantly reduced in the presence of 20 microM or 100 microM prednisolone. LTB4, LTC4, LTD4, and histamine stimulated the rate of TXB2 production during 1 min incubation to 93-, 49-, 60-, and 55-fold, respectively.
Substance Class Chemical
Created
by admin
on Tue Oct 22 06:05:00 UTC 2019
Edited
by admin
on Tue Oct 22 06:05:00 UTC 2019
Record UNII
71099P640P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PREDNAZATE
INN   USAN  
USAN   INN  
Official Name English
11.BETA.,17,21-TRIHYDROXYPREGNA-1,4-DIENE-3,20-DIONE, 21-(HYDROGEN SUCCINATE), COMPOUND WITH 4-(3-(2-CHLOROPHENOTHIAZIN-10-YL)PROPYL)-1-PIPERAZINEETHANOL (1:1)
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 21-(3-CARBOXY-1-OXOPROPOXY)-11,17-DIHYDROXY-, (11.BETA.)-, COMPD. WITH 4-(3-(2-CHLORO-10H-PHENOTHIAZIN-10-YL)PROPYL)-1-PIPERAZINEETHANOL (1:1)
Common Name English
66-20
Code English
PREDNISOLONE 21-HEMISUCCINATE PERPHENAZINE (1:1)
Common Name English
PREDNAZATE [INN]
Common Name English
SCH-6620
Code English
PREDNAZATE [USAN]
Common Name English
SCH 6620
Code English
Classification Tree Code System Code
NCI_THESAURUS C2356
Created by admin on Tue Oct 22 06:05:00 UTC 2019 , Edited by admin on Tue Oct 22 06:05:00 UTC 2019
Code System Code Type Description
EVMPD
SUB10013MIG
Created by admin on Tue Oct 22 06:05:01 UTC 2019 , Edited by admin on Tue Oct 22 06:05:01 UTC 2019
PRIMARY
CAS
5714-75-0
Created by admin on Tue Oct 22 06:05:01 UTC 2019 , Edited by admin on Tue Oct 22 06:05:01 UTC 2019
PRIMARY
INN
1944
Created by admin on Tue Oct 22 06:05:00 UTC 2019 , Edited by admin on Tue Oct 22 06:05:00 UTC 2019
PRIMARY
PUBCHEM
10010848
Created by admin on Tue Oct 22 06:05:00 UTC 2019 , Edited by admin on Tue Oct 22 06:05:00 UTC 2019
PRIMARY
NCI_THESAURUS
C82228
Created by admin on Tue Oct 22 06:05:01 UTC 2019 , Edited by admin on Tue Oct 22 06:05:01 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY
ACTIVE MOIETY